|
|
 Previous Article | Table of Contents | Next Article 
Possible effect of secretor locus on plasma concentration of factor VIII
and von Willebrand factor
KH Orstavik, L Kornstad, H Reisner and K Berg
Institute of Medical Genetics, University of Oslo, Norway.
A significant fraction (30%) of the genetically determined variance in
plasma concentration of the von Willebrand factor antigen (vWf:Ag) has been
shown to be related to ABH determinants. Individuals with blood group O,
who have the highest amounts of blood group H substance, have the lowest
concentration of vWf:Ag. The Lewis substances, Le(a) and Le(b), are
biochemically closely related to the ABH substances as both can be produced
from the same precursor substance. We studied the effect of the presence of
the Lewis antigens on the plasma concentration of vWf:Ag and factor VIII
antigen (VIII:Ag) in 323 individuals of different ABO groups from a series
of twins and in 58 blood donors of blood group O. Among persons belonging
to blood group O, those with the Le(a) antigen had a higher concentration
of both vWf:Ag and VIII:Ag than individuals lacking Le(a). Le(a+b-) people
are nonsecretors and Le(a-b+) people are secretors of ABH substance. Thus,
the lowest concentration of vWf:Ag and VIII:Ag was found in group O
secretors. The effect is most likely due to an effect of the secretor
locus. This finding may be of importance for the detection of carriers of
hemophilia A and for the diagnosis of type I von Willebrand disease.
Volume 73,
Issue 4,
pp. 990-993,
03/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Ribeiro, G. D. Salton, E. Bandinelli, A. R. Oliveira, and I. Roisenberg
The Effect of ABO Blood Group on von Willebrand Response to Exercise
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2008;
14(4):
454 - 458.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. J. Kunicki, A. B. Federici, D. R. Salomon, J. A. Koziol, S. R. Head, T. S. Mondala, J. D. Chismar, L. Baronciani, M. T. Canciani, and I. R. Peake
An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees
Blood,
October 15, 2004;
104(8):
2359 - 2367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Sadler
Von Willebrand disease type 1: a diagnosis in search of a disease
Blood,
March 15, 2003;
101(6):
2089 - 2093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Ellies, D. Ditto, G. G. Levy, M. Wahrenbrock, D. Ginsburg, A. Varki, D. T. Le, and J. D. Marth
Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands
PNAS,
July 23, 2002;
99(15):
10042 - 10047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, R. K. Pruthi, and W. L. Nichols
Acquired von Willebrand Disease
Mayo Clin. Proc.,
February 1, 2002;
77(2):
181 - 187.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. C. Souto, L. Almasy, E. Muniz-Diaz, J. M. Soria, M. Borrell, L. Bayen, J. Mateo, P. Madoz, W. Stone, J. Blangero, et al.
Functional Effects of the ABO Locus Polymorphism on Plasma Levels of von Willebrand Factor, Factor VIII, and Activated Partial Thromboplastin Time
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2000;
20(8):
2024 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mohri, S. Motomura, H. Kanamori, M. Matsuzaki, S.-i. Watanabe, A. Maruta, F. Kodama, and T. Okubo
Clinical Significance of Inhibitors in Acquired von Willebrand Syndrome
Blood,
May 15, 1998;
91(10):
3623 - 3629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Mohlke, W. C. Nichols, R. J. Westrick, E. K. Novak, K. A. Cooney, R. T. Swank, and D. Ginsburg
A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11
PNAS,
December 24, 1996;
93(26):
15352 - 15357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
